Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2423studies indexed1086with human data145registered trials2091carry a numeric findingLibrarian added 0 studies today
Showing 22 studiesSortNewest indexed ▾
C
grade
Detection of LongR<sup>3</sup> -IGF-I, Des(1-3)-IGF-I, and R<sup>3</sup> -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.
IGF-1 DES (Des(1-3) IGF-1) · Drug testing and analysis · 2021 · Observational · Preclinical
The study found that Des(1-3)-IGF-I and R<sup>3</sup>-IGF-I can be detected in rats for up to 24 hours after a single injection, while LongR<sup>3</sup>-IGF-I is undetectable after 4 hours.
Des(1-3)-IGF-I and R<sup>3</sup>-IGF-I detectable until 24 h after 100 μg/kg IM injection in rats.
B
grade
Bethesda Endoscopic Retrograde Cholangiopancreatography Skill Assessment Tool (BESAT)-Based Simulator Training Using a Novel Dry Endoscopic Retrograde Cholangiopancreatography Model Improves Technical Proficiency and Self-Efficacy: A Prospective Study.
IGF-1 DES (Des(1-3) IGF-1) · DEN open · 2026 · Observational · n=30
Simulator-based training significantly boosts EST success rates and trainee confidence, but real-world applicability needs further validation.
EST success rate increased from 43.3% to 76.7% (p < 0.05).
A
grade
Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial.
IGF-1 DES (Des(1-3) IGF-1) · The lancet. Healthy longevity · 2026 · RCT · Phase 3 · n=1160Top journal
Discontinuation of statins in older adults aged 75 and above who have no history of cardiovascular disease does not seem to increase the risk of death compared to continuing statin therapy.
The absolute difference in all-cause mortality between groups was -0.68% (95% CI -3.95 to 2.60).
A
grade
Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.
IGF-1 DES (Des(1-3) IGF-1) · Annals of the rheumatic diseases · 2026 · RCT · Phase 3 · n=495
Filgotinib showed significant improvements in symptoms for patients with axial spondyloarthritis compared to placebo, but further research is needed to assess long-term safety and efficacy.
39.5% ASAS40 response in r-axSpA filgotinib group vs 20.9% PBO, P=0.001, n=258.
B
grade
Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytoma and oligodendroglioma, WHO grade 2
IGF-1 DES (Des(1-3) IGF-1) · biorxiv-preprint · 2025 · Observational
The spontaneous growth rate of IDHmt low-grade gliomas varies significantly between codeleted and non-codeleted subtypes, which may influence treatment strategies.
Median TVGR was 0.241 year -1 for codeleted LGG vs 0.424 year -1 for non-codeleted LGG, p<0.001.
D
grade
Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.
IGF-1 DES (Des(1-3) IGF-1) · europepmc · 2025 · Meta-analysis
This study identified 91 genetic loci associated with Alzheimer's disease risk, including 16 new loci, but further validation is needed to confirm their clinical relevance.
Twofold increased risk of presenting with Braak neurofibrillary tangles stage of >4 in the tenth decile of the polygenic score compared to median score group.
Showing 22 of 22